nodes	percent_of_prediction	percent_of_DWPC	metapath
Nefazodone—CYP3A5—prostate cancer	0.198	0.698	CbGaD
Nefazodone—CYP3A4—prostate cancer	0.0859	0.302	CbGaD
Nefazodone—CYP3A5—Flutamide—prostate cancer	0.0275	0.0684	CbGbCtD
Nefazodone—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.0246	0.0613	CbGbCtD
Nefazodone—CYP2D6—Bicalutamide—prostate cancer	0.0203	0.0507	CbGbCtD
Nefazodone—CYP3A5—Cabazitaxel—prostate cancer	0.0203	0.0506	CbGbCtD
Nefazodone—ABCB1—Estramustine—prostate cancer	0.0201	0.05	CbGbCtD
Nefazodone—CYP3A5—Estrone—prostate cancer	0.0199	0.0495	CbGbCtD
Nefazodone—CYP2D6—Abiraterone—prostate cancer	0.0169	0.042	CbGbCtD
Nefazodone—ADRA1B—vas deferens—prostate cancer	0.0165	0.51	CbGeAlD
Nefazodone—CYP3A7-CYP3A51P—Estradiol—prostate cancer	0.0152	0.0379	CbGbCtD
Nefazodone—CYP3A7—Estradiol—prostate cancer	0.0152	0.0379	CbGbCtD
Nefazodone—ABCB1—Cabazitaxel—prostate cancer	0.0132	0.033	CbGbCtD
Nefazodone—CYP3A4—Bicalutamide—prostate cancer	0.0129	0.0322	CbGbCtD
Nefazodone—ABCB1—Estrone—prostate cancer	0.0129	0.0322	CbGbCtD
Nefazodone—CYP3A4—Estramustine—prostate cancer	0.012	0.0299	CbGbCtD
Nefazodone—ABCB1—Ethinyl Estradiol—prostate cancer	0.0115	0.0287	CbGbCtD
Nefazodone—CYP3A5—Estradiol—prostate cancer	0.0114	0.0284	CbGbCtD
Nefazodone—CYP3A4—Abiraterone—prostate cancer	0.0107	0.0267	CbGbCtD
Nefazodone—CYP3A4—Flutamide—prostate cancer	0.0107	0.0267	CbGbCtD
Nefazodone—CYP3A7-CYP3A51P—Docetaxel—prostate cancer	0.00909	0.0226	CbGbCtD
Nefazodone—CYP3A7—Docetaxel—prostate cancer	0.00909	0.0226	CbGbCtD
Nefazodone—ABCB1—Conjugated Estrogens—prostate cancer	0.00846	0.0211	CbGbCtD
Nefazodone—CYP3A4—Cabazitaxel—prostate cancer	0.00793	0.0197	CbGbCtD
Nefazodone—CYP3A4—Estrone—prostate cancer	0.00775	0.0193	CbGbCtD
Nefazodone—ABCB1—Mitoxantrone—prostate cancer	0.00769	0.0192	CbGbCtD
Nefazodone—CYP3A5—Etoposide—prostate cancer	0.00745	0.0186	CbGbCtD
Nefazodone—ABCB1—Estradiol—prostate cancer	0.00743	0.0185	CbGbCtD
Nefazodone—CYP3A4—Ethinyl Estradiol—prostate cancer	0.0069	0.0172	CbGbCtD
Nefazodone—CYP3A5—Docetaxel—prostate cancer	0.00682	0.017	CbGbCtD
Nefazodone—ABCB1—Prednisone—prostate cancer	0.00639	0.0159	CbGbCtD
Nefazodone—CYP3A4—Conjugated Estrogens—prostate cancer	0.00507	0.0126	CbGbCtD
Nefazodone—ABCB1—Etoposide—prostate cancer	0.00485	0.0121	CbGbCtD
Nefazodone—CYP3A4—Mitoxantrone—prostate cancer	0.00461	0.0115	CbGbCtD
Nefazodone—CYP3A4—Estradiol—prostate cancer	0.00445	0.0111	CbGbCtD
Nefazodone—ABCB1—Docetaxel—prostate cancer	0.00444	0.0111	CbGbCtD
Nefazodone—CYP3A4—Prednisone—prostate cancer	0.00383	0.00953	CbGbCtD
Nefazodone—ABCB1—Doxorubicin—prostate cancer	0.00331	0.00824	CbGbCtD
Nefazodone—CYP2D6—Doxorubicin—prostate cancer	0.00312	0.00776	CbGbCtD
Nefazodone—CYP3A4—Etoposide—prostate cancer	0.00291	0.00724	CbGbCtD
Nefazodone—CYP3A4—Docetaxel—prostate cancer	0.00266	0.00662	CbGbCtD
Nefazodone—CYP3A4—Doxorubicin—prostate cancer	0.00198	0.00494	CbGbCtD
Nefazodone—HTR2A—urine—prostate cancer	0.00149	0.046	CbGeAlD
Nefazodone—CYP3A4—urine—prostate cancer	0.00138	0.0426	CbGeAlD
Nefazodone—CYP2D6—urine—prostate cancer	0.00136	0.0419	CbGeAlD
Nefazodone—ADRA1B—renal system—prostate cancer	0.001	0.031	CbGeAlD
Nefazodone—ADRA1A—prostate gland—prostate cancer	0.000827	0.0256	CbGeAlD
Nefazodone—CYP3A5—prostate gland—prostate cancer	0.000659	0.0204	CbGeAlD
Nefazodone—ADRA2A—prostate gland—prostate cancer	0.000628	0.0194	CbGeAlD
Nefazodone—HTR1A—renal system—prostate cancer	0.000611	0.0189	CbGeAlD
Nefazodone—ADRA1A—epithelium—prostate cancer	0.000607	0.0188	CbGeAlD
Nefazodone—ADRA1A—renal system—prostate cancer	0.000563	0.0174	CbGeAlD
Nefazodone—ADRA2A—seminal vesicle—prostate cancer	0.000532	0.0164	CbGeAlD
Nefazodone—SLC6A3—testis—prostate cancer	0.000486	0.015	CbGeAlD
Nefazodone—CYP3A5—renal system—prostate cancer	0.000449	0.0139	CbGeAlD
Nefazodone—ADRA2A—urethra—prostate cancer	0.000421	0.013	CbGeAlD
Nefazodone—Perphenazine—AOX1—prostate cancer	0.000398	0.18	CrCbGaD
Nefazodone—HTR2A—epithelium—prostate cancer	0.000393	0.0121	CbGeAlD
Nefazodone—SLC6A2—testis—prostate cancer	0.000392	0.0121	CbGeAlD
Nefazodone—HTR2A—renal system—prostate cancer	0.000364	0.0113	CbGeAlD
Nefazodone—ABCB1—prostate gland—prostate cancer	0.00035	0.0108	CbGeAlD
Nefazodone—CYP3A4—renal system—prostate cancer	0.000337	0.0104	CbGeAlD
Nefazodone—CYP2D6—renal system—prostate cancer	0.000332	0.0103	CbGeAlD
Nefazodone—ABCB1—seminal vesicle—prostate cancer	0.000296	0.00916	CbGeAlD
Nefazodone—SLC6A2—lymph node—prostate cancer	0.000284	0.00878	CbGeAlD
Nefazodone—ADRA2A—testis—prostate cancer	0.000277	0.00856	CbGeAlD
Nefazodone—ABCB1—epithelium—prostate cancer	0.000257	0.00796	CbGeAlD
Nefazodone—ABCB1—renal system—prostate cancer	0.000239	0.00738	CbGeAlD
Nefazodone—Domperidone—CYP3A5—prostate cancer	0.000238	0.108	CrCbGaD
Nefazodone—HTR2A—testis—prostate cancer	0.000235	0.00728	CbGeAlD
Nefazodone—ABCB1—urethra—prostate cancer	0.000234	0.00725	CbGeAlD
Nefazodone—Thioproperazine—SLC22A1—prostate cancer	0.000216	0.098	CrCbGaD
Nefazodone—CYP2D6—testis—prostate cancer	0.000214	0.00663	CbGeAlD
Nefazodone—ADRA2A—lymph node—prostate cancer	0.000201	0.00621	CbGeAlD
Nefazodone—Aripiprazole—CYP3A5—prostate cancer	0.000184	0.0834	CrCbGaD
Nefazodone—Trazodone—CYP3A5—prostate cancer	0.000183	0.083	CrCbGaD
Nefazodone—ABCB1—bone marrow—prostate cancer	0.00018	0.00558	CbGeAlD
Nefazodone—Perphenazine—CYP2C18—prostate cancer	0.000178	0.0807	CrCbGaD
Nefazodone—ABCB1—testis—prostate cancer	0.000154	0.00477	CbGeAlD
Nefazodone—Quetiapine—CYP3A5—prostate cancer	0.000115	0.0521	CrCbGaD
Nefazodone—ABCB1—lymph node—prostate cancer	0.000112	0.00346	CbGeAlD
Nefazodone—Domperidone—CYP3A4—prostate cancer	0.000103	0.0468	CrCbGaD
Nefazodone—Fluphenazine—CYP2E1—prostate cancer	0.000102	0.0462	CrCbGaD
Nefazodone—Perphenazine—CYP2C19—prostate cancer	7.98e-05	0.0362	CrCbGaD
Nefazodone—Aripiprazole—CYP3A4—prostate cancer	7.96e-05	0.0361	CrCbGaD
Nefazodone—Trazodone—CYP3A4—prostate cancer	7.93e-05	0.0359	CrCbGaD
Nefazodone—Quetiapine—CYP2C19—prostate cancer	7.83e-05	0.0355	CrCbGaD
Nefazodone—Prochlorperazine—CYP3A4—prostate cancer	7.1e-05	0.0322	CrCbGaD
Nefazodone—Perphenazine—CYP3A4—prostate cancer	5.08e-05	0.023	CrCbGaD
Nefazodone—Quetiapine—CYP3A4—prostate cancer	4.98e-05	0.0226	CrCbGaD
Nefazodone—Conjunctivitis—Doxorubicin—prostate cancer	3.62e-05	0.000191	CcSEcCtD
Nefazodone—Urinary tract infection—Doxorubicin—prostate cancer	3.62e-05	0.000191	CcSEcCtD
Nefazodone—Vertigo—Prednisone—prostate cancer	3.62e-05	0.000191	CcSEcCtD
Nefazodone—Haemorrhage—Epirubicin—prostate cancer	3.62e-05	0.000191	CcSEcCtD
Nefazodone—Hepatitis—Epirubicin—prostate cancer	3.62e-05	0.000191	CcSEcCtD
Nefazodone—Thrombocytopenia—Capecitabine—prostate cancer	3.61e-05	0.00019	CcSEcCtD
Nefazodone—Syncope—Prednisone—prostate cancer	3.61e-05	0.00019	CcSEcCtD
Nefazodone—Tachycardia—Capecitabine—prostate cancer	3.6e-05	0.00019	CcSEcCtD
Nefazodone—Hypoaesthesia—Epirubicin—prostate cancer	3.6e-05	0.00019	CcSEcCtD
Nefazodone—Pharyngitis—Epirubicin—prostate cancer	3.59e-05	0.000189	CcSEcCtD
Nefazodone—Sweating—Doxorubicin—prostate cancer	3.57e-05	0.000188	CcSEcCtD
Nefazodone—Hyperhidrosis—Capecitabine—prostate cancer	3.56e-05	0.000188	CcSEcCtD
Nefazodone—Oedema peripheral—Epirubicin—prostate cancer	3.56e-05	0.000188	CcSEcCtD
Nefazodone—Hypotension—Docetaxel—prostate cancer	3.56e-05	0.000188	CcSEcCtD
Nefazodone—Haematuria—Doxorubicin—prostate cancer	3.55e-05	0.000187	CcSEcCtD
Nefazodone—Loss of consciousness—Prednisone—prostate cancer	3.54e-05	0.000187	CcSEcCtD
Nefazodone—Epistaxis—Doxorubicin—prostate cancer	3.52e-05	0.000185	CcSEcCtD
Nefazodone—Anorexia—Capecitabine—prostate cancer	3.52e-05	0.000185	CcSEcCtD
Nefazodone—Nausea—Estradiol—prostate cancer	3.51e-05	0.000185	CcSEcCtD
Nefazodone—Vomiting—Mitoxantrone—prostate cancer	3.5e-05	0.000185	CcSEcCtD
Nefazodone—Sinusitis—Doxorubicin—prostate cancer	3.5e-05	0.000184	CcSEcCtD
Nefazodone—Convulsion—Prednisone—prostate cancer	3.49e-05	0.000184	CcSEcCtD
Nefazodone—Visual impairment—Epirubicin—prostate cancer	3.48e-05	0.000184	CcSEcCtD
Nefazodone—Hypertension—Prednisone—prostate cancer	3.47e-05	0.000183	CcSEcCtD
Nefazodone—Rash—Mitoxantrone—prostate cancer	3.47e-05	0.000183	CcSEcCtD
Nefazodone—Dermatitis—Mitoxantrone—prostate cancer	3.47e-05	0.000183	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Docetaxel—prostate cancer	3.47e-05	0.000183	CcSEcCtD
Nefazodone—Headache—Mitoxantrone—prostate cancer	3.45e-05	0.000182	CcSEcCtD
Nefazodone—Hypotension—Capecitabine—prostate cancer	3.45e-05	0.000182	CcSEcCtD
Nefazodone—Insomnia—Docetaxel—prostate cancer	3.44e-05	0.000182	CcSEcCtD
Nefazodone—Arthralgia—Prednisone—prostate cancer	3.43e-05	0.000181	CcSEcCtD
Nefazodone—Myalgia—Prednisone—prostate cancer	3.43e-05	0.000181	CcSEcCtD
Nefazodone—Paraesthesia—Docetaxel—prostate cancer	3.42e-05	0.00018	CcSEcCtD
Nefazodone—Erythema multiforme—Epirubicin—prostate cancer	3.42e-05	0.00018	CcSEcCtD
Nefazodone—Anxiety—Prednisone—prostate cancer	3.41e-05	0.00018	CcSEcCtD
Nefazodone—Bradycardia—Doxorubicin—prostate cancer	3.41e-05	0.00018	CcSEcCtD
Nefazodone—Dyspnoea—Docetaxel—prostate cancer	3.4e-05	0.000179	CcSEcCtD
Nefazodone—Somnolence—Docetaxel—prostate cancer	3.39e-05	0.000179	CcSEcCtD
Nefazodone—Discomfort—Prednisone—prostate cancer	3.39e-05	0.000179	CcSEcCtD
Nefazodone—Hypersensitivity—Etoposide—prostate cancer	3.38e-05	0.000178	CcSEcCtD
Nefazodone—Tinnitus—Epirubicin—prostate cancer	3.37e-05	0.000178	CcSEcCtD
Nefazodone—Haemoglobin—Doxorubicin—prostate cancer	3.36e-05	0.000177	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Capecitabine—prostate cancer	3.36e-05	0.000177	CcSEcCtD
Nefazodone—Flushing—Epirubicin—prostate cancer	3.36e-05	0.000177	CcSEcCtD
Nefazodone—Rhinitis—Doxorubicin—prostate cancer	3.35e-05	0.000177	CcSEcCtD
Nefazodone—Dyspepsia—Docetaxel—prostate cancer	3.35e-05	0.000177	CcSEcCtD
Nefazodone—Hepatitis—Doxorubicin—prostate cancer	3.35e-05	0.000176	CcSEcCtD
Nefazodone—Haemorrhage—Doxorubicin—prostate cancer	3.35e-05	0.000176	CcSEcCtD
Nefazodone—Insomnia—Capecitabine—prostate cancer	3.34e-05	0.000176	CcSEcCtD
Nefazodone—Hypoaesthesia—Doxorubicin—prostate cancer	3.33e-05	0.000176	CcSEcCtD
Nefazodone—Pharyngitis—Doxorubicin—prostate cancer	3.32e-05	0.000175	CcSEcCtD
Nefazodone—Paraesthesia—Capecitabine—prostate cancer	3.31e-05	0.000175	CcSEcCtD
Nefazodone—Decreased appetite—Docetaxel—prostate cancer	3.31e-05	0.000175	CcSEcCtD
Nefazodone—Oedema peripheral—Doxorubicin—prostate cancer	3.3e-05	0.000174	CcSEcCtD
Nefazodone—Asthenia—Etoposide—prostate cancer	3.29e-05	0.000173	CcSEcCtD
Nefazodone—Dyspnoea—Capecitabine—prostate cancer	3.29e-05	0.000173	CcSEcCtD
Nefazodone—Anaphylactic shock—Prednisone—prostate cancer	3.28e-05	0.000173	CcSEcCtD
Nefazodone—Oedema—Prednisone—prostate cancer	3.28e-05	0.000173	CcSEcCtD
Nefazodone—Nausea—Mitoxantrone—prostate cancer	3.27e-05	0.000173	CcSEcCtD
Nefazodone—Infection—Prednisone—prostate cancer	3.26e-05	0.000172	CcSEcCtD
Nefazodone—Constipation—Docetaxel—prostate cancer	3.26e-05	0.000172	CcSEcCtD
Nefazodone—Pain—Docetaxel—prostate cancer	3.26e-05	0.000172	CcSEcCtD
Nefazodone—Dyspepsia—Capecitabine—prostate cancer	3.25e-05	0.000171	CcSEcCtD
Nefazodone—Chills—Epirubicin—prostate cancer	3.24e-05	0.000171	CcSEcCtD
Nefazodone—Pruritus—Etoposide—prostate cancer	3.24e-05	0.000171	CcSEcCtD
Nefazodone—Shock—Prednisone—prostate cancer	3.23e-05	0.00017	CcSEcCtD
Nefazodone—Visual impairment—Doxorubicin—prostate cancer	3.22e-05	0.00017	CcSEcCtD
Nefazodone—Tachycardia—Prednisone—prostate cancer	3.21e-05	0.000169	CcSEcCtD
Nefazodone—Decreased appetite—Capecitabine—prostate cancer	3.21e-05	0.000169	CcSEcCtD
Nefazodone—Alopecia—Epirubicin—prostate cancer	3.2e-05	0.000169	CcSEcCtD
Nefazodone—Hyperhidrosis—Prednisone—prostate cancer	3.18e-05	0.000168	CcSEcCtD
Nefazodone—Erythema multiforme—Doxorubicin—prostate cancer	3.16e-05	0.000167	CcSEcCtD
Nefazodone—Constipation—Capecitabine—prostate cancer	3.15e-05	0.000166	CcSEcCtD
Nefazodone—Pain—Capecitabine—prostate cancer	3.15e-05	0.000166	CcSEcCtD
Nefazodone—Feeling abnormal—Docetaxel—prostate cancer	3.14e-05	0.000166	CcSEcCtD
Nefazodone—Diarrhoea—Etoposide—prostate cancer	3.14e-05	0.000165	CcSEcCtD
Nefazodone—Anorexia—Prednisone—prostate cancer	3.13e-05	0.000165	CcSEcCtD
Nefazodone—Tinnitus—Doxorubicin—prostate cancer	3.12e-05	0.000165	CcSEcCtD
Nefazodone—Gastrointestinal pain—Docetaxel—prostate cancer	3.11e-05	0.000164	CcSEcCtD
Nefazodone—Flushing—Doxorubicin—prostate cancer	3.11e-05	0.000164	CcSEcCtD
Nefazodone—Flatulence—Epirubicin—prostate cancer	3.1e-05	0.000164	CcSEcCtD
Nefazodone—Dysgeusia—Epirubicin—prostate cancer	3.08e-05	0.000163	CcSEcCtD
Nefazodone—Back pain—Epirubicin—prostate cancer	3.04e-05	0.000161	CcSEcCtD
Nefazodone—Feeling abnormal—Capecitabine—prostate cancer	3.04e-05	0.00016	CcSEcCtD
Nefazodone—Dizziness—Etoposide—prostate cancer	3.03e-05	0.00016	CcSEcCtD
Nefazodone—Muscle spasms—Epirubicin—prostate cancer	3.03e-05	0.00016	CcSEcCtD
Nefazodone—Gastrointestinal pain—Capecitabine—prostate cancer	3.02e-05	0.000159	CcSEcCtD
Nefazodone—Abdominal pain—Docetaxel—prostate cancer	3.01e-05	0.000159	CcSEcCtD
Nefazodone—Body temperature increased—Docetaxel—prostate cancer	3.01e-05	0.000159	CcSEcCtD
Nefazodone—Chills—Doxorubicin—prostate cancer	3e-05	0.000158	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Prednisone—prostate cancer	2.99e-05	0.000158	CcSEcCtD
Nefazodone—Insomnia—Prednisone—prostate cancer	2.97e-05	0.000157	CcSEcCtD
Nefazodone—Vision blurred—Epirubicin—prostate cancer	2.97e-05	0.000156	CcSEcCtD
Nefazodone—Alopecia—Doxorubicin—prostate cancer	2.96e-05	0.000156	CcSEcCtD
Nefazodone—Paraesthesia—Prednisone—prostate cancer	2.95e-05	0.000156	CcSEcCtD
Nefazodone—Urticaria—Capecitabine—prostate cancer	2.93e-05	0.000155	CcSEcCtD
Nefazodone—Ill-defined disorder—Epirubicin—prostate cancer	2.92e-05	0.000154	CcSEcCtD
Nefazodone—Abdominal pain—Capecitabine—prostate cancer	2.92e-05	0.000154	CcSEcCtD
Nefazodone—Body temperature increased—Capecitabine—prostate cancer	2.92e-05	0.000154	CcSEcCtD
Nefazodone—Vomiting—Etoposide—prostate cancer	2.91e-05	0.000154	CcSEcCtD
Nefazodone—Anaemia—Epirubicin—prostate cancer	2.91e-05	0.000153	CcSEcCtD
Nefazodone—Agitation—Epirubicin—prostate cancer	2.89e-05	0.000153	CcSEcCtD
Nefazodone—Dyspepsia—Prednisone—prostate cancer	2.89e-05	0.000153	CcSEcCtD
Nefazodone—Rash—Etoposide—prostate cancer	2.89e-05	0.000152	CcSEcCtD
Nefazodone—Dermatitis—Etoposide—prostate cancer	2.89e-05	0.000152	CcSEcCtD
Nefazodone—Headache—Etoposide—prostate cancer	2.87e-05	0.000151	CcSEcCtD
Nefazodone—Flatulence—Doxorubicin—prostate cancer	2.87e-05	0.000151	CcSEcCtD
Nefazodone—Decreased appetite—Prednisone—prostate cancer	2.86e-05	0.000151	CcSEcCtD
Nefazodone—Dysgeusia—Doxorubicin—prostate cancer	2.85e-05	0.00015	CcSEcCtD
Nefazodone—Malaise—Epirubicin—prostate cancer	2.84e-05	0.00015	CcSEcCtD
Nefazodone—Vertigo—Epirubicin—prostate cancer	2.83e-05	0.000149	CcSEcCtD
Nefazodone—Syncope—Epirubicin—prostate cancer	2.82e-05	0.000149	CcSEcCtD
Nefazodone—Leukopenia—Epirubicin—prostate cancer	2.82e-05	0.000149	CcSEcCtD
Nefazodone—Back pain—Doxorubicin—prostate cancer	2.82e-05	0.000149	CcSEcCtD
Nefazodone—Constipation—Prednisone—prostate cancer	2.81e-05	0.000148	CcSEcCtD
Nefazodone—Hypersensitivity—Docetaxel—prostate cancer	2.81e-05	0.000148	CcSEcCtD
Nefazodone—Muscle spasms—Doxorubicin—prostate cancer	2.8e-05	0.000148	CcSEcCtD
Nefazodone—Palpitations—Epirubicin—prostate cancer	2.78e-05	0.000147	CcSEcCtD
Nefazodone—Loss of consciousness—Epirubicin—prostate cancer	2.77e-05	0.000146	CcSEcCtD
Nefazodone—Cough—Epirubicin—prostate cancer	2.75e-05	0.000145	CcSEcCtD
Nefazodone—Vision blurred—Doxorubicin—prostate cancer	2.74e-05	0.000145	CcSEcCtD
Nefazodone—Asthenia—Docetaxel—prostate cancer	2.73e-05	0.000144	CcSEcCtD
Nefazodone—Convulsion—Epirubicin—prostate cancer	2.73e-05	0.000144	CcSEcCtD
Nefazodone—Nausea—Etoposide—prostate cancer	2.72e-05	0.000144	CcSEcCtD
Nefazodone—Hypertension—Epirubicin—prostate cancer	2.72e-05	0.000143	CcSEcCtD
Nefazodone—Hypersensitivity—Capecitabine—prostate cancer	2.72e-05	0.000143	CcSEcCtD
Nefazodone—Feeling abnormal—Prednisone—prostate cancer	2.71e-05	0.000143	CcSEcCtD
Nefazodone—Ill-defined disorder—Doxorubicin—prostate cancer	2.7e-05	0.000143	CcSEcCtD
Nefazodone—Pruritus—Docetaxel—prostate cancer	2.69e-05	0.000142	CcSEcCtD
Nefazodone—Anaemia—Doxorubicin—prostate cancer	2.69e-05	0.000142	CcSEcCtD
Nefazodone—Gastrointestinal pain—Prednisone—prostate cancer	2.69e-05	0.000142	CcSEcCtD
Nefazodone—Chest pain—Epirubicin—prostate cancer	2.68e-05	0.000141	CcSEcCtD
Nefazodone—Arthralgia—Epirubicin—prostate cancer	2.68e-05	0.000141	CcSEcCtD
Nefazodone—Myalgia—Epirubicin—prostate cancer	2.68e-05	0.000141	CcSEcCtD
Nefazodone—Agitation—Doxorubicin—prostate cancer	2.68e-05	0.000141	CcSEcCtD
Nefazodone—Anxiety—Epirubicin—prostate cancer	2.67e-05	0.000141	CcSEcCtD
Nefazodone—Discomfort—Epirubicin—prostate cancer	2.65e-05	0.00014	CcSEcCtD
Nefazodone—Asthenia—Capecitabine—prostate cancer	2.65e-05	0.00014	CcSEcCtD
Nefazodone—Malaise—Doxorubicin—prostate cancer	2.63e-05	0.000139	CcSEcCtD
Nefazodone—Dry mouth—Epirubicin—prostate cancer	2.62e-05	0.000138	CcSEcCtD
Nefazodone—Vertigo—Doxorubicin—prostate cancer	2.62e-05	0.000138	CcSEcCtD
Nefazodone—Syncope—Doxorubicin—prostate cancer	2.61e-05	0.000138	CcSEcCtD
Nefazodone—Urticaria—Prednisone—prostate cancer	2.61e-05	0.000138	CcSEcCtD
Nefazodone—Pruritus—Capecitabine—prostate cancer	2.61e-05	0.000138	CcSEcCtD
Nefazodone—Leukopenia—Doxorubicin—prostate cancer	2.61e-05	0.000138	CcSEcCtD
Nefazodone—Diarrhoea—Docetaxel—prostate cancer	2.61e-05	0.000137	CcSEcCtD
Nefazodone—Body temperature increased—Prednisone—prostate cancer	2.6e-05	0.000137	CcSEcCtD
Nefazodone—Abdominal pain—Prednisone—prostate cancer	2.6e-05	0.000137	CcSEcCtD
Nefazodone—Confusional state—Epirubicin—prostate cancer	2.59e-05	0.000137	CcSEcCtD
Nefazodone—Palpitations—Doxorubicin—prostate cancer	2.57e-05	0.000136	CcSEcCtD
Nefazodone—Oedema—Epirubicin—prostate cancer	2.57e-05	0.000136	CcSEcCtD
Nefazodone—Anaphylactic shock—Epirubicin—prostate cancer	2.57e-05	0.000136	CcSEcCtD
Nefazodone—Loss of consciousness—Doxorubicin—prostate cancer	2.56e-05	0.000135	CcSEcCtD
Nefazodone—Infection—Epirubicin—prostate cancer	2.55e-05	0.000135	CcSEcCtD
Nefazodone—Cough—Doxorubicin—prostate cancer	2.54e-05	0.000134	CcSEcCtD
Nefazodone—Shock—Epirubicin—prostate cancer	2.53e-05	0.000133	CcSEcCtD
Nefazodone—Convulsion—Doxorubicin—prostate cancer	2.52e-05	0.000133	CcSEcCtD
Nefazodone—Diarrhoea—Capecitabine—prostate cancer	2.52e-05	0.000133	CcSEcCtD
Nefazodone—Dizziness—Docetaxel—prostate cancer	2.52e-05	0.000133	CcSEcCtD
Nefazodone—Thrombocytopenia—Epirubicin—prostate cancer	2.52e-05	0.000133	CcSEcCtD
Nefazodone—Hypertension—Doxorubicin—prostate cancer	2.51e-05	0.000133	CcSEcCtD
Nefazodone—Tachycardia—Epirubicin—prostate cancer	2.51e-05	0.000132	CcSEcCtD
Nefazodone—Hyperhidrosis—Epirubicin—prostate cancer	2.48e-05	0.000131	CcSEcCtD
Nefazodone—Arthralgia—Doxorubicin—prostate cancer	2.48e-05	0.000131	CcSEcCtD
Nefazodone—Myalgia—Doxorubicin—prostate cancer	2.48e-05	0.000131	CcSEcCtD
Nefazodone—Chest pain—Doxorubicin—prostate cancer	2.48e-05	0.000131	CcSEcCtD
Nefazodone—Anxiety—Doxorubicin—prostate cancer	2.47e-05	0.00013	CcSEcCtD
Nefazodone—Discomfort—Doxorubicin—prostate cancer	2.45e-05	0.000129	CcSEcCtD
Nefazodone—Anorexia—Epirubicin—prostate cancer	2.45e-05	0.000129	CcSEcCtD
Nefazodone—Dizziness—Capecitabine—prostate cancer	2.44e-05	0.000129	CcSEcCtD
Nefazodone—Dry mouth—Doxorubicin—prostate cancer	2.43e-05	0.000128	CcSEcCtD
Nefazodone—Vomiting—Docetaxel—prostate cancer	2.42e-05	0.000128	CcSEcCtD
Nefazodone—Hypersensitivity—Prednisone—prostate cancer	2.42e-05	0.000128	CcSEcCtD
Nefazodone—Rash—Docetaxel—prostate cancer	2.4e-05	0.000127	CcSEcCtD
Nefazodone—Hypotension—Epirubicin—prostate cancer	2.4e-05	0.000127	CcSEcCtD
Nefazodone—Dermatitis—Docetaxel—prostate cancer	2.4e-05	0.000127	CcSEcCtD
Nefazodone—Confusional state—Doxorubicin—prostate cancer	2.4e-05	0.000126	CcSEcCtD
Nefazodone—Headache—Docetaxel—prostate cancer	2.39e-05	0.000126	CcSEcCtD
Nefazodone—Anaphylactic shock—Doxorubicin—prostate cancer	2.38e-05	0.000125	CcSEcCtD
Nefazodone—Oedema—Doxorubicin—prostate cancer	2.38e-05	0.000125	CcSEcCtD
Nefazodone—Infection—Doxorubicin—prostate cancer	2.36e-05	0.000125	CcSEcCtD
Nefazodone—Asthenia—Prednisone—prostate cancer	2.36e-05	0.000124	CcSEcCtD
Nefazodone—Vomiting—Capecitabine—prostate cancer	2.34e-05	0.000124	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Epirubicin—prostate cancer	2.34e-05	0.000123	CcSEcCtD
Nefazodone—Shock—Doxorubicin—prostate cancer	2.34e-05	0.000123	CcSEcCtD
Nefazodone—Thrombocytopenia—Doxorubicin—prostate cancer	2.33e-05	0.000123	CcSEcCtD
Nefazodone—Rash—Capecitabine—prostate cancer	2.33e-05	0.000123	CcSEcCtD
Nefazodone—Pruritus—Prednisone—prostate cancer	2.32e-05	0.000123	CcSEcCtD
Nefazodone—Insomnia—Epirubicin—prostate cancer	2.32e-05	0.000123	CcSEcCtD
Nefazodone—Dermatitis—Capecitabine—prostate cancer	2.32e-05	0.000123	CcSEcCtD
Nefazodone—Tachycardia—Doxorubicin—prostate cancer	2.32e-05	0.000122	CcSEcCtD
Nefazodone—Headache—Capecitabine—prostate cancer	2.31e-05	0.000122	CcSEcCtD
Nefazodone—Paraesthesia—Epirubicin—prostate cancer	2.31e-05	0.000122	CcSEcCtD
Nefazodone—Hyperhidrosis—Doxorubicin—prostate cancer	2.3e-05	0.000121	CcSEcCtD
Nefazodone—Dyspnoea—Epirubicin—prostate cancer	2.29e-05	0.000121	CcSEcCtD
Nefazodone—Somnolence—Epirubicin—prostate cancer	2.28e-05	0.00012	CcSEcCtD
Nefazodone—Anorexia—Doxorubicin—prostate cancer	2.27e-05	0.00012	CcSEcCtD
Nefazodone—Nausea—Docetaxel—prostate cancer	2.26e-05	0.000119	CcSEcCtD
Nefazodone—Dyspepsia—Epirubicin—prostate cancer	2.26e-05	0.000119	CcSEcCtD
Nefazodone—Diarrhoea—Prednisone—prostate cancer	2.25e-05	0.000119	CcSEcCtD
Nefazodone—Decreased appetite—Epirubicin—prostate cancer	2.23e-05	0.000118	CcSEcCtD
Nefazodone—Hypotension—Doxorubicin—prostate cancer	2.22e-05	0.000117	CcSEcCtD
Nefazodone—Pain—Epirubicin—prostate cancer	2.2e-05	0.000116	CcSEcCtD
Nefazodone—Constipation—Epirubicin—prostate cancer	2.2e-05	0.000116	CcSEcCtD
Nefazodone—Nausea—Capecitabine—prostate cancer	2.19e-05	0.000116	CcSEcCtD
Nefazodone—Dizziness—Prednisone—prostate cancer	2.17e-05	0.000115	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Doxorubicin—prostate cancer	2.17e-05	0.000114	CcSEcCtD
Nefazodone—Insomnia—Doxorubicin—prostate cancer	2.15e-05	0.000113	CcSEcCtD
Nefazodone—Paraesthesia—Doxorubicin—prostate cancer	2.13e-05	0.000113	CcSEcCtD
Nefazodone—Dyspnoea—Doxorubicin—prostate cancer	2.12e-05	0.000112	CcSEcCtD
Nefazodone—Feeling abnormal—Epirubicin—prostate cancer	2.12e-05	0.000112	CcSEcCtD
Nefazodone—Somnolence—Doxorubicin—prostate cancer	2.11e-05	0.000111	CcSEcCtD
Nefazodone—Gastrointestinal pain—Epirubicin—prostate cancer	2.1e-05	0.000111	CcSEcCtD
Nefazodone—Dyspepsia—Doxorubicin—prostate cancer	2.09e-05	0.00011	CcSEcCtD
Nefazodone—Vomiting—Prednisone—prostate cancer	2.09e-05	0.00011	CcSEcCtD
Nefazodone—Rash—Prednisone—prostate cancer	2.07e-05	0.000109	CcSEcCtD
Nefazodone—Dermatitis—Prednisone—prostate cancer	2.07e-05	0.000109	CcSEcCtD
Nefazodone—Decreased appetite—Doxorubicin—prostate cancer	2.07e-05	0.000109	CcSEcCtD
Nefazodone—Headache—Prednisone—prostate cancer	2.06e-05	0.000109	CcSEcCtD
Nefazodone—Urticaria—Epirubicin—prostate cancer	2.04e-05	0.000108	CcSEcCtD
Nefazodone—Pain—Doxorubicin—prostate cancer	2.03e-05	0.000107	CcSEcCtD
Nefazodone—Constipation—Doxorubicin—prostate cancer	2.03e-05	0.000107	CcSEcCtD
Nefazodone—Abdominal pain—Epirubicin—prostate cancer	2.03e-05	0.000107	CcSEcCtD
Nefazodone—Body temperature increased—Epirubicin—prostate cancer	2.03e-05	0.000107	CcSEcCtD
Nefazodone—Feeling abnormal—Doxorubicin—prostate cancer	1.96e-05	0.000103	CcSEcCtD
Nefazodone—Nausea—Prednisone—prostate cancer	1.95e-05	0.000103	CcSEcCtD
Nefazodone—Gastrointestinal pain—Doxorubicin—prostate cancer	1.94e-05	0.000103	CcSEcCtD
Nefazodone—Hypersensitivity—Epirubicin—prostate cancer	1.89e-05	9.98e-05	CcSEcCtD
Nefazodone—Urticaria—Doxorubicin—prostate cancer	1.89e-05	9.96e-05	CcSEcCtD
Nefazodone—Abdominal pain—Doxorubicin—prostate cancer	1.88e-05	9.91e-05	CcSEcCtD
Nefazodone—Body temperature increased—Doxorubicin—prostate cancer	1.88e-05	9.91e-05	CcSEcCtD
Nefazodone—Asthenia—Epirubicin—prostate cancer	1.84e-05	9.72e-05	CcSEcCtD
Nefazodone—Pruritus—Epirubicin—prostate cancer	1.82e-05	9.59e-05	CcSEcCtD
Nefazodone—Diarrhoea—Epirubicin—prostate cancer	1.76e-05	9.27e-05	CcSEcCtD
Nefazodone—Hypersensitivity—Doxorubicin—prostate cancer	1.75e-05	9.24e-05	CcSEcCtD
Nefazodone—Asthenia—Doxorubicin—prostate cancer	1.71e-05	9e-05	CcSEcCtD
Nefazodone—Dizziness—Epirubicin—prostate cancer	1.7e-05	8.96e-05	CcSEcCtD
Nefazodone—Pruritus—Doxorubicin—prostate cancer	1.68e-05	8.87e-05	CcSEcCtD
Nefazodone—Vomiting—Epirubicin—prostate cancer	1.63e-05	8.62e-05	CcSEcCtD
Nefazodone—Diarrhoea—Doxorubicin—prostate cancer	1.63e-05	8.58e-05	CcSEcCtD
Nefazodone—Rash—Epirubicin—prostate cancer	1.62e-05	8.54e-05	CcSEcCtD
Nefazodone—Dermatitis—Epirubicin—prostate cancer	1.62e-05	8.54e-05	CcSEcCtD
Nefazodone—Headache—Epirubicin—prostate cancer	1.61e-05	8.49e-05	CcSEcCtD
Nefazodone—Dizziness—Doxorubicin—prostate cancer	1.57e-05	8.29e-05	CcSEcCtD
Nefazodone—Nausea—Epirubicin—prostate cancer	1.53e-05	8.05e-05	CcSEcCtD
Nefazodone—Vomiting—Doxorubicin—prostate cancer	1.51e-05	7.97e-05	CcSEcCtD
Nefazodone—Rash—Doxorubicin—prostate cancer	1.5e-05	7.91e-05	CcSEcCtD
Nefazodone—Dermatitis—Doxorubicin—prostate cancer	1.5e-05	7.9e-05	CcSEcCtD
Nefazodone—Headache—Doxorubicin—prostate cancer	1.49e-05	7.85e-05	CcSEcCtD
Nefazodone—Nausea—Doxorubicin—prostate cancer	1.41e-05	7.45e-05	CcSEcCtD
Nefazodone—ADRA1B—Signaling Pathways—ERBB2—prostate cancer	2.08e-06	2.31e-05	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—PIK3CA—prostate cancer	2.07e-06	2.3e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—CXCL8—prostate cancer	2.07e-06	2.3e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—SERPINE1—prostate cancer	2.07e-06	2.3e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—CXCL8—prostate cancer	2.06e-06	2.29e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—PIK3CB—prostate cancer	2.06e-06	2.28e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—MTHFR—prostate cancer	2.05e-06	2.28e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CREBBP—prostate cancer	2.05e-06	2.28e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—SLC5A5—prostate cancer	2.05e-06	2.28e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—KRAS—prostate cancer	2.05e-06	2.27e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—FGF2—prostate cancer	2.05e-06	2.27e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—PIK3CB—prostate cancer	2.03e-06	2.25e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—IGF1—prostate cancer	2.03e-06	2.25e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—CDKN1B—prostate cancer	2.03e-06	2.25e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—NOS3—prostate cancer	2.02e-06	2.24e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—EGFR—prostate cancer	2.02e-06	2.24e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—CDKN1B—prostate cancer	2.02e-06	2.24e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PPARA—prostate cancer	2.01e-06	2.23e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—NOS3—prostate cancer	2.01e-06	2.23e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—PTGS2—prostate cancer	2.01e-06	2.23e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—CAV1—prostate cancer	2.01e-06	2.23e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—FGF2—prostate cancer	2.01e-06	2.22e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—CYP2E1—prostate cancer	2e-06	2.22e-05	CbGpPWpGaD
Nefazodone—HTR1A—GPCR downstream signaling—AKT1—prostate cancer	2e-06	2.22e-05	CbGpPWpGaD
Nefazodone—HTR2C—GPCR downstream signaling—AKT1—prostate cancer	1.99e-06	2.21e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—CASP3—prostate cancer	1.99e-06	2.2e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—IL2—prostate cancer	1.98e-06	2.2e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—NQO1—prostate cancer	1.98e-06	2.2e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—NOS3—prostate cancer	1.98e-06	2.19e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CXCL8—prostate cancer	1.98e-06	2.19e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—CASP3—prostate cancer	1.98e-06	2.19e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—IL6—prostate cancer	1.97e-06	2.19e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—IL2—prostate cancer	1.97e-06	2.19e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—JAK2—prostate cancer	1.96e-06	2.18e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—IL6—prostate cancer	1.96e-06	2.18e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—MAP2K1—prostate cancer	1.96e-06	2.17e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—TH—prostate cancer	1.95e-06	2.17e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—PIK3CD—prostate cancer	1.95e-06	2.16e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—CCND1—prostate cancer	1.93e-06	2.14e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CDKN1B—prostate cancer	1.93e-06	2.14e-05	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—PIK3CA—prostate cancer	1.93e-06	2.14e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—SERPINE1—prostate cancer	1.93e-06	2.14e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—PIK3CA—prostate cancer	1.92e-06	2.13e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—JAK2—prostate cancer	1.92e-06	2.13e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—CCND1—prostate cancer	1.92e-06	2.13e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—MDM2—prostate cancer	1.92e-06	2.13e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—CTNNB1—prostate cancer	1.91e-06	2.12e-05	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR downstream signaling—AKT1—prostate cancer	1.91e-06	2.12e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—KRAS—prostate cancer	1.91e-06	2.11e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—CTNNB1—prostate cancer	1.9e-06	2.11e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—CYP1B1—prostate cancer	1.9e-06	2.11e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—CAV1—prostate cancer	1.89e-06	2.1e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CASP3—prostate cancer	1.89e-06	2.1e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—ERBB2—prostate cancer	1.89e-06	2.1e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—IL2—prostate cancer	1.89e-06	2.09e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—PIK3CA—prostate cancer	1.88e-06	2.09e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—IL6—prostate cancer	1.88e-06	2.08e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—MDM2—prostate cancer	1.88e-06	2.08e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—MMP9—prostate cancer	1.88e-06	2.08e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—CDKN1A—prostate cancer	1.87e-06	2.07e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—MMP9—prostate cancer	1.87e-06	2.07e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—PTEN—prostate cancer	1.87e-06	2.07e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—PIK3CB—prostate cancer	1.86e-06	2.07e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—FGF2—prostate cancer	1.86e-06	2.07e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—CDKN1A—prostate cancer	1.86e-06	2.06e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—PIK3CB—prostate cancer	1.86e-06	2.06e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—PTEN—prostate cancer	1.86e-06	2.06e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—ERBB2—prostate cancer	1.85e-06	2.05e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—PTGS2—prostate cancer	1.84e-06	2.04e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—GGT1—prostate cancer	1.84e-06	2.04e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CCND1—prostate cancer	1.84e-06	2.04e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—NOS3—prostate cancer	1.84e-06	2.04e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PIK3CG—prostate cancer	1.83e-06	2.03e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—PIK3CB—prostate cancer	1.83e-06	2.03e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CTNNB1—prostate cancer	1.82e-06	2.02e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—AKT1—prostate cancer	1.82e-06	2.02e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—NCOA1—prostate cancer	1.81e-06	2.01e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—AKT1—prostate cancer	1.81e-06	2.01e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CXCL8—prostate cancer	1.79e-06	1.99e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—MMP9—prostate cancer	1.79e-06	1.98e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—CYP19A1—prostate cancer	1.79e-06	1.98e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—JAK2—prostate cancer	1.79e-06	1.98e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CDKN1A—prostate cancer	1.78e-06	1.97e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—EP300—prostate cancer	1.78e-06	1.97e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—PTEN—prostate cancer	1.78e-06	1.97e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—EP300—prostate cancer	1.77e-06	1.96e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CXCL8—prostate cancer	1.75e-06	1.95e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—PTEN—prostate cancer	1.75e-06	1.94e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—PIK3CA—prostate cancer	1.75e-06	1.94e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CDKN1B—prostate cancer	1.75e-06	1.94e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—MDM2—prostate cancer	1.74e-06	1.93e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—INS—prostate cancer	1.73e-06	1.92e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—AKT1—prostate cancer	1.73e-06	1.92e-05	CbGpPWpGaD
Nefazodone—HTR2A—GPCR downstream signaling—AKT1—prostate cancer	1.73e-06	1.92e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—SRC—prostate cancer	1.73e-06	1.92e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PIK3CG—prostate cancer	1.73e-06	1.91e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—RXRA—prostate cancer	1.72e-06	1.91e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—SRC—prostate cancer	1.72e-06	1.91e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—ERBB2—prostate cancer	1.72e-06	1.91e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CASP3—prostate cancer	1.72e-06	1.9e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CDKN1B—prostate cancer	1.71e-06	1.9e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—IL2—prostate cancer	1.71e-06	1.9e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—IL6—prostate cancer	1.7e-06	1.89e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—CREBBP—prostate cancer	1.7e-06	1.88e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—PIK3CB—prostate cancer	1.7e-06	1.88e-05	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—AKT1—prostate cancer	1.7e-06	1.88e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—EP300—prostate cancer	1.69e-06	1.88e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—VEGFA—prostate cancer	1.68e-06	1.87e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CASP3—prostate cancer	1.68e-06	1.86e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—IL2—prostate cancer	1.68e-06	1.86e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—VEGFA—prostate cancer	1.68e-06	1.86e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—EP300—prostate cancer	1.67e-06	1.85e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CCND1—prostate cancer	1.67e-06	1.85e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—IL6—prostate cancer	1.67e-06	1.85e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—STAT3—prostate cancer	1.67e-06	1.85e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—COMT—prostate cancer	1.66e-06	1.84e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—STAT3—prostate cancer	1.66e-06	1.84e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CTNNB1—prostate cancer	1.65e-06	1.83e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—GSTP1—prostate cancer	1.65e-06	1.83e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—SRC—prostate cancer	1.65e-06	1.83e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CCND1—prostate cancer	1.63e-06	1.81e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—INS—prostate cancer	1.63e-06	1.81e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CXCL8—prostate cancer	1.63e-06	1.81e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—ITPR1—prostate cancer	1.63e-06	1.8e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—MMP9—prostate cancer	1.62e-06	1.8e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CTNNB1—prostate cancer	1.62e-06	1.8e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CDKN1A—prostate cancer	1.62e-06	1.79e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—PTEN—prostate cancer	1.61e-06	1.79e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PIK3CD—prostate cancer	1.61e-06	1.79e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—PTEN—prostate cancer	1.61e-06	1.78e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—VEGFA—prostate cancer	1.6e-06	1.78e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—CREBBP—prostate cancer	1.6e-06	1.77e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CDKN1B—prostate cancer	1.59e-06	1.77e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—STAT3—prostate cancer	1.59e-06	1.76e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—MMP9—prostate cancer	1.59e-06	1.76e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CDKN1A—prostate cancer	1.58e-06	1.75e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—PTEN—prostate cancer	1.58e-06	1.75e-05	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—AKT1—prostate cancer	1.57e-06	1.75e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—AKT1—prostate cancer	1.57e-06	1.74e-05	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—PIK3CA—prostate cancer	1.57e-06	1.74e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CASP3—prostate cancer	1.56e-06	1.73e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—IL2—prostate cancer	1.56e-06	1.73e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—IL6—prostate cancer	1.55e-06	1.72e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—MYC—prostate cancer	1.55e-06	1.72e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—TGFB1—prostate cancer	1.55e-06	1.71e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—MYC—prostate cancer	1.54e-06	1.71e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—AKT1—prostate cancer	1.54e-06	1.71e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—TGFB1—prostate cancer	1.54e-06	1.71e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—TYMS—prostate cancer	1.54e-06	1.7e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—EP300—prostate cancer	1.54e-06	1.7e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—EP300—prostate cancer	1.53e-06	1.7e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—NOS3—prostate cancer	1.52e-06	1.69e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—GSTM1—prostate cancer	1.52e-06	1.68e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CCND1—prostate cancer	1.52e-06	1.68e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PIK3CD—prostate cancer	1.52e-06	1.68e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—EGFR—prostate cancer	1.52e-06	1.68e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—EGFR—prostate cancer	1.51e-06	1.67e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—EP300—prostate cancer	1.5e-06	1.67e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CTNNB1—prostate cancer	1.5e-06	1.67e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—SRC—prostate cancer	1.49e-06	1.66e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—LPL—prostate cancer	1.49e-06	1.65e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—MYC—prostate cancer	1.48e-06	1.64e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—MMP9—prostate cancer	1.47e-06	1.64e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—TGFB1—prostate cancer	1.47e-06	1.63e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CDKN1A—prostate cancer	1.47e-06	1.63e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—PTEN—prostate cancer	1.47e-06	1.63e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—SRC—prostate cancer	1.46e-06	1.62e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—VEGFA—prostate cancer	1.46e-06	1.61e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—EGFR—prostate cancer	1.44e-06	1.6e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—STAT3—prostate cancer	1.44e-06	1.6e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—CYP1A1—prostate cancer	1.44e-06	1.6e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—NOS3—prostate cancer	1.43e-06	1.59e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—KRAS—prostate cancer	1.43e-06	1.59e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—AKT1—prostate cancer	1.43e-06	1.59e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—ERCC2—prostate cancer	1.43e-06	1.58e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—VEGFA—prostate cancer	1.43e-06	1.58e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—KRAS—prostate cancer	1.42e-06	1.58e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—STAT3—prostate cancer	1.41e-06	1.57e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PIK3CB—prostate cancer	1.4e-06	1.56e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—EP300—prostate cancer	1.4e-06	1.55e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PTGS2—prostate cancer	1.39e-06	1.54e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—KRAS—prostate cancer	1.36e-06	1.51e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—SRC—prostate cancer	1.36e-06	1.51e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—MTHFR—prostate cancer	1.34e-06	1.49e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—MYC—prostate cancer	1.34e-06	1.49e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—TGFB1—prostate cancer	1.34e-06	1.48e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—VEGFA—prostate cancer	1.32e-06	1.47e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PIK3CB—prostate cancer	1.32e-06	1.47e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PPARA—prostate cancer	1.32e-06	1.46e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—PIK3CA—prostate cancer	1.32e-06	1.46e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—MYC—prostate cancer	1.31e-06	1.45e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—STAT3—prostate cancer	1.31e-06	1.45e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PTGS2—prostate cancer	1.31e-06	1.45e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—EGFR—prostate cancer	1.31e-06	1.45e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—PIK3CA—prostate cancer	1.31e-06	1.45e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—TGFB1—prostate cancer	1.31e-06	1.45e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—EGFR—prostate cancer	1.28e-06	1.42e-05	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—AKT1—prostate cancer	1.28e-06	1.42e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—TP53—prostate cancer	1.27e-06	1.41e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—TP53—prostate cancer	1.27e-06	1.4e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—PIK3CA—prostate cancer	1.25e-06	1.39e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—CAV1—prostate cancer	1.24e-06	1.37e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—KRAS—prostate cancer	1.24e-06	1.37e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—PIK3CA—prostate cancer	1.24e-06	1.37e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—MYC—prostate cancer	1.22e-06	1.35e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—TGFB1—prostate cancer	1.22e-06	1.35e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PTEN—prostate cancer	1.21e-06	1.34e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—TP53—prostate cancer	1.21e-06	1.34e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—KRAS—prostate cancer	1.21e-06	1.34e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—EGFR—prostate cancer	1.19e-06	1.32e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—IL6—prostate cancer	1.17e-06	1.29e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—IL6—prostate cancer	1.16e-06	1.29e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—EP300—prostate cancer	1.16e-06	1.28e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PTEN—prostate cancer	1.14e-06	1.27e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—PIK3CA—prostate cancer	1.14e-06	1.26e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—PIK3CA—prostate cancer	1.13e-06	1.26e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PIK3CG—prostate cancer	1.13e-06	1.25e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—KRAS—prostate cancer	1.13e-06	1.25e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—PIK3CA—prostate cancer	1.11e-06	1.23e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—IL6—prostate cancer	1.11e-06	1.23e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—TP53—prostate cancer	1.1e-06	1.22e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—EP300—prostate cancer	1.09e-06	1.21e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—TP53—prostate cancer	1.08e-06	1.19e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—AKT1—prostate cancer	1.07e-06	1.19e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—AKT1—prostate cancer	1.07e-06	1.19e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—INS—prostate cancer	1.07e-06	1.18e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—CREBBP—prostate cancer	1.05e-06	1.16e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—PIK3CA—prostate cancer	1.03e-06	1.15e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—AKT1—prostate cancer	1.02e-06	1.14e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—AKT1—prostate cancer	1.01e-06	1.12e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—IL6—prostate cancer	1.01e-06	1.12e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—TP53—prostate cancer	1e-06	1.11e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PIK3CD—prostate cancer	9.92e-07	1.1e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—IL6—prostate cancer	9.86e-07	1.09e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—NOS3—prostate cancer	9.36e-07	1.04e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—AKT1—prostate cancer	9.29e-07	1.03e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—AKT1—prostate cancer	9.26e-07	1.03e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—IL6—prostate cancer	9.16e-07	1.02e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—AKT1—prostate cancer	9.09e-07	1.01e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PIK3CB—prostate cancer	8.64e-07	9.59e-06	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PTGS2—prostate cancer	8.56e-07	9.5e-06	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PIK3CA—prostate cancer	8.55e-07	9.49e-06	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—AKT1—prostate cancer	8.45e-07	9.37e-06	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PIK3CA—prostate cancer	8.06e-07	8.94e-06	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PTEN—prostate cancer	7.47e-07	8.28e-06	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—EP300—prostate cancer	7.12e-07	7.9e-06	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—AKT1—prostate cancer	6.99e-07	7.75e-06	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—AKT1—prostate cancer	6.58e-07	7.3e-06	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PIK3CA—prostate cancer	5.27e-07	5.84e-06	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—AKT1—prostate cancer	4.3e-07	4.77e-06	CbGpPWpGaD
